Before you read on, please be aware that the analysis below is my opinion only and may include flawed assumptions and inaccuracy of logic; therefore, caveat emptor applies here. Furthermore, all emphasis (color-coded, boldness, and underlined) on the excerpts are my own.
What bits & pieces?
There are many knowledgeable investors out there sharing information on $TRXC, and I came upon one which I believe all investors MUST READ. But first, I like to give credit to the EdWill93 for posting the link to the MUST READ article.
Let’s start with EdWill93’s post:
The link below will take you to the abstract of the article, “First Experiences with the New Senhance® Telerobotic System in Visceral Surgery“:
And the link below will give you the whole article to read.
From the article, I’m amazed at the level of details offering how well the Senhance supported the laparoscopic surgical procedures. The prominent message I picked up from the article is how IMPORTANT the followings are:
- hybrid surgery
- haptic feedback
- independent arms with their own bases
- reusable instruments
- Low learning curve due to Senhance following laparoscopy protocols
- Procedure cost is same if not lower than manual lap surgery
As I researched more on $TRXC week after week, I’m learning more and more about the company and Senhance. From the article, my overall impression is that the feature of hybrid surgery is an important selling point for the laparoscopy surgeons. Due to Senhance’s ability to allow surgeons to place the robotic arms out of the way without sacrificing both patient positioning and robotic arms placement, hybrid surgery is made possible.
Therefore, for this week, I’m going to let the full article, “First Experiences with the New Senhance® Telerobotic System in Visceral Surgery” speaks for itself. And for those who missed the post by EdWill93 (which I almost did), my suggestion is that you do not want to miss reading this article if you are long $TRXC.
And I agreed with EdWill93 wholeheartedly regarding his statement, “if you have any doubts, First Experiences with the New Senhance® Telerobotic System in Visceral Surgery“. In other words, if you have any doubts, the article may help you eliminated them.
Again, thanks to EdWill93 at Stocktwit for providing the link to the abstract.
Don’t forget; all the above are my opinions only!
Good Luck and may fortune blesses all TRXC investors.
My 2 cents.
From my camera: